【ChiCTR2000040970】An Acceptance and Commitment Therapy – Caregiver Support Program (ACT-CSP) for family caregivers of patients receiving palliative care: A feasibility study
ChiCTR2000040970
正在进行
/
/
/
2020-12-16
/
/
Caregivers of palliative care patients
An Acceptance and Commitment Therapy – Caregiver Support Program (ACT-CSP) for family caregivers of patients receiving palliative care: A feasibility study
An Acceptance and Commitment Therapy – Caregiver Support Program (ACT-CSP) for family caregivers of patients receiving palliative care: A feasibility study
1) To test the feasibility, acceptability and preliminary efficacy of an acceptance and commitment therapy for supporting caregiver programme (ACT-CSP) on reduction of caregiver burden, anxiety and depressive symptoms and enhancement of caregiving self-efficacy, resilience and quality of life by ACT when compared to usual care, for caregivers of palliative care patients; 2) To explore ACTs potential impact on patients symptom burden.
随机平行对照
其它
After collecting participant's informed consent, a research assistant will randomly assign the participant to either ACT-CSP or TAU arm using the pre-prepared envelopes. Caregivers will be randomized to either the two arms by block randomization with varying block sizes.
Both the caregivers and the intervention facilitator cannot be blinded due to the intervention nature. All the outcome assessors will be blinded.
Departmental General Research Fund
/
40
/
2021-02-01
2023-01-31
/
Caregivers will be eligible if they are (1) aged >=18 years; (2) self- or patient-identified as a family caregiver of an adult patient receiving palliative care at the study site; (3) have been taking care of the patient in the past 3 months; (4) able to communicate in Cantonese at the time of recruitment；
请登录查看Caregivers will be excluded if they are (1) mentally incompetent (Mini-Mental State Examination (MMSE) < 23); (2) participating in regular psychosocial interventions.；
请登录查看香港理工大學護理學院
/
香港理工大學護理學院的其他临床试验
香港理工大學護理學院的其他临床试验
最新临床资讯
-
诺华：CFB抑制剂终止狼疮肾炎二期临床
医药笔记2026-10-17
-
泽安生物医药：实体瘤MCE启动一期临床
医药笔记2026-10-17
-
药明康德2026-10-17
-
沃森生物2026-10-16
-
罕见病信息网2026-10-16
-
武警特色医学中心2026-10-16
-
生物经纬2026-10-16
-
良医汇肿瘤资讯2026-10-16
-
BioMed科技2026-10-16
-
蒲公英资讯2026-10-16
全球药物研发中心
全球研发数据与行业前沿情报
研发动态
相关报告
政策法规
-
2026-10-26
-
2026-10-25
-
2026-10-25
-
摩熵咨询 33 51
-
摩熵咨询 20 3
-
摩熵咨询 20 10
-
颁布机构：国家药品审评中心（CDE） 2026-10-16
-
颁布机构：国家药品监督管理局药品审评中心 2026-09-28
-
颁布机构：国家药品监督管理局 2026-09-10
医药市场洞察中心
医药市场销售数据分析 · 智能洞察 · 竞争格局监测
-
医药市场销售数据分析 · 医院、实体药店、网上药店
-
市场竞争格局分析(靶点、药品类型、ATC大类)
市场动态
市场报告
政策法规
-
2026-10-23
-
2026-10-23
-
2026-10-21
-
摩熵咨询 35 83
-
摩熵咨询 28 71
-
摩熵咨询 34 47
-
颁布机构：国家药品监督管理局 2026-10-19
-
颁布机构：国家市场监督管理总局 2026-10-16
-
颁布机构：国家市场监督管理总局 2026-09-30